90年代开发成功的格列吡嗪控释片是目前唯一采用胃肠道治疗系统技术制备的新型磺脲类降糖药。它仅需每日一次就能提供 2 4小时强化血糖控制和生理性胰岛素反应 ,同时又保持格列吡嗪良好的安全性。 1994年经美国 FDA批准先后在美国、欧洲乃至全球上市 ,成为治疗 2型糖尿病的一线 The glipizide controlled release tablets developed in the 90s are the only new sulfonylurea hypoglycemic agents that are currently prepared by the gastrointestinal treatment system technology. It provides 24 hours of intensive glycemic control and physiological insulin response only once daily, while maintaining the good safety of glipizide. Approved by the US FDA in 1994, it has been listed in the United States, Europe and the world as a first-line treatment of type 2 diabetes